Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study
Tóm tắt
To assess the clinical relevance of a history of atrial fibrillation (AF) in hospitalized patients with coronavirus disease 2019 (COVID-19).
We enrolled 696 consecutive patients (mean age 67.4 ± 13.2 years, 69.7% males) admitted for COVID-19 in 13 Italian cardiology centres between 1 March and 9 April 2020. One hundred and six patients (15%) had a history of AF and the median hospitalization length was 14 days (interquartile range 9–24). Patients with a history of AF were older and with a higher burden of cardiovascular risk factors. Compared to patients without AF, they showed a higher rate of in-hospital death (38.7% vs. 20.8%; P < 0.001). History of AF was associated with an increased risk of death after adjustment for clinical confounders related to COVID-19 severity and cardiovascular comorbidities, including history of heart failure (HF) and increased plasma troponin [adjusted hazard ratio (HR): 1.73; 95% confidence interval (CI) 1.06–2.84; P = 0.029]. Patients with a history of AF also had more in-hospital clinical events including new-onset AF (36.8% vs. 7.9%; P < 0.001), acute HF (25.3% vs. 6.3%; P < 0.001), and multiorgan failure (13.9% vs. 5.8%; P = 0.010). The association between AF and worse outcome was not modified by previous or concomitant use of anticoagulants or steroid therapy (P for interaction >0.05 for both) and was not related to stroke or bleeding events.
Among hospitalized patients with COVID-19, a history of AF contributes to worse clinical course with a higher mortality and in-hospital events including new-onset AF, acute HF, and multiorgan failure. The mortality risk remains significant after adjustment for variables associated with COVID-19 severity and comorbidities.
Từ khóa
Tài liệu tham khảo
Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032
Tomasoni, 2020, COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease, Eur J Heart Fail, 22, 957, 10.1002/ejhf.1871
Gopinathannair, 2020, COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies, J Interv Card Electrophysiol, 59, 329, 10.1007/s10840-020-00789-9
Denegri, 2021, Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection, Intern Emerg Med, 4, 1
Lombardi, 2020, Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: results of a multicenter study, JAMA Cardiol, 5, 1274, 10.1001/jamacardio.2020.3538
Hindricks, 2020, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, 498
Tomasoni, 2020, Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study, Eur J Heart Fail, 22, 2238, 10.1002/ejhf.2052
Peltzer, 2020, Arrhythmic complications of patients hospitalized with COVID-19: incidence, risk factors, and outcomes, Circ Arrhythm Electrophysiol, 13, e009121, 10.1161/CIRCEP.120.009121
Colon, 2020, Atrial arrhythmias in COVID-19 patients, JACC Clin Electrophysiol, 6, 1189, 10.1016/j.jacep.2020.05.015
Bertini, 2020, Electrocardiographic features of 431 consecutive, critically ill COVID-19 patients: an insight into the mechanisms of cardiac involvement, Europace, 22, 1848, 10.1093/europace/euaa258
Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 811, 10.1001/jamacardio.2020.1017
Inciardi, 2020, Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy, Eur Heart J, 41, 1821, 10.1093/eurheartj/ehaa388
Peltzer, 2020, Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19, J Cardiovasc Electrophysiol, 31, 3077, 10.1111/jce.14770
Schnabel, 2015, 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study, Lancet, 386, 154, 10.1016/S0140-6736(14)61774-8
Inciardi, 2019, Left atrial structure and function and the risk of death or heart failure in atrial fibrillation, Eur J Heart Fail, 21, 1571, 10.1002/ejhf.1606
Shaver, 2015, Atrial fibrillation is an independent predictor of mortality in critically ill patients, Crit Care Med, 43, 2104, 10.1097/CCM.0000000000001166
Inciardi, 2020, Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk?, Eur Heart J, 41, 3094, 10.1093/eurheartj/ehaa576
Inciardi, 2020, Disease (COVID-19), systemic inflammation, and cardiovascular disease, J Am Heart Assoc, 9, e017756, 10.1161/JAHA.120.017756
Flam, 2020, Direct oral anticoagulant use and risk of severe COVID-19, J Intern Med, 10, 1111
Rattanawong, 2020, Guidance on short-term management of atrial fibrillation in coronavirus disease 2019, J Am Heart Assoc, 9, e017529, 10.1161/JAHA.120.017529
ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic